Akèy › Kansè Poumon ki pa ti selil › Texas › Irving
Etid klinik pou Kansè Poumon ki pa ti selil nan Irving, TX
22 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Irving (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #73, Irving
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Ap rekriteFaz 1
- NEXT Dallas, Irving
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- US Oncology Investigational Product Center (IPC), Irving
- US Oncology Investigational Products Center (IPC), Irving
- US Oncology Investigational Products Center(IPC), Irving
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- US Oncology Investigational Products Center (IPC), Irving
- US Oncology Investigational Products Center, Irving
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Ap rekriteFaz 3
- US Oncology Research Investigational Products Center, Irving
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Ap rekriteFaz 1/2
- US Oncology Investigational Products Center (IPC), Irving
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- NEXT Oncology - Irving, Irving
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- NEXT Dallas, Irving
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Ap rekriteFaz 1/2
- Next Oncology - Dallas, Irving
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Ap rekriteFaz 2/3
- Local Institution - 007-999, Irving
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Ap rekriteFaz 1/2
- Next Oncology Dallas, Irving
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Ap rekriteFaz 1/2
- NEXT Dallas - Oncology Department, Irving
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Ap rekriteFaz 1/2
- NEXT Dallas, Irving
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Dallas, Irving
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- US Oncology Investigational Product Center (IPC), Irving
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- NEXT Oncology Dallas, Irving
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- Next Oncology Dallas /ID# 276254, Irving
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Ap rekriteFaz 1
- NEXT Texas LLC - Dallas, Irving
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology Dallas, Irving
A 2-part Phase 1/2 Open-label Trial on ODM-212
Ap rekriteFaz 1/2
- NEXT Oncology, Irving
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Ap rekriteFaz 1/2
- NEXT, Dallas, Irving
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Ap rekriteFaz 1/2
- NEXT Dallas, Irving
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY120 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH56 etid
- Washington, DC55 etid
Lòt etid nan Irving
- Kansè (tout kalite)15 etid
- Kansè kolorektal13 etid
- Kansè Metastatik11 etid
- Kansè pankreyas7 etid
- Kansè lestomak7 etid
- Karsinòm selil skuamèz tèt ak kou6 etid
- Kansè nan tete6 etid
- Kansè poumon selil ti6 etid
- Kansè poumon6 etid
- Kansè ovè5 etid
- Kansè Endomèt4 etid
- Kansè pwostat4 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.